The Therapeutic Respiratory Devices Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The primary factors driving the growth of the therapeutic respiratory devices market are an increase in the frequency and incidence of respiratory disorders, technical innovation, and increasing government and non-governmental organisation support for respiratory disease healthcare awareness. Increasing awareness of respiratory disorders among the general population and governments is predicted to improve the market for respiratory medicine delivery products.
Airsep Corporation (Chart Industries)
AptarGroup, Inc.
AstraZeneca
Becton, Dickinson and Company (BD)
Boehringer Ingelheim International GmbH
Cipla Inc.
Fisher & Paykel Healthcare Limited
GE Healthcare
GF Health Products, Inc.
GSK plc
Hamilton Medical
Invacare
Koninklijke Philips N.V.
Medisana GmbH
Medtronic
Merck & Co., Inc.
Novartis AG
OMRON Corporation
Recipharm AB
ResMed
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Smiths Medical, Inc.
Sunovion Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Overall world revenue for Therapeutic Respiratory Devices Market, 2023 to 2033 in terms of value the market will surpass US$63 billion in 2023, this work calculates. We predict strong revenue growth through to 2033. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Rising Prevalence of Respiratory Diseases Driving Market Growth
The number of respiratory disorders is growing globally due to a variety of causes such as pollution, lifestyle choices, and smoking. According to WHO, an estimated 65 million individuals have moderate to severe chronic obstructive pulmonary disease (COPD), with around 3 million dying each year, making it the world's third greatest cause of death and the number is growing. About 334 million people worldwide are suffering from asthma, childhood's most frequent chronic condition, impacting 14% of children. The frequency of asthma in children is rising.The primary factors driving the growth of the therapeutic respiratory devices market are an increase in the frequency and incidence of respiratory disorders, technical innovation, and increasing government and non-governmental organisation support for respiratory disease healthcare awareness. Increasing awareness of respiratory disorders among the general population and governments is predicted to improve the market for respiratory medicine delivery products.
Limited Reimbursements Likely to Hamper Market Growth
Patients' reimbursements are frequently used to pay for medical services. There is now a reimbursement gap in the diagnostic sector as a whole, and in respiratory therapy diagnostics in particular. The reimbursement schemes for PAP equipment and oral appliances differ across Europe and are only applicable in a few countries (devices not covered by insurance represent a small share of the market in the region). Moreover, respiratory care equipment is not fully covered by insurance in the majority of Asian and RoW nations. Over the projected period, high cost of therapeutic respiratory devices is likely to further constrain the market.What Questions Should You Ask before Buying a Market Research Report?
- How is the therapeutic respiratory devices market evolving?
- What is driving and restraining the therapeutic respiratory devices market?
- How will each therapeutic respiratory devices submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each therapeutic respiratory devices submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading therapeutic respiratory devices markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the therapeutic respiratory devices projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of therapeutic respiratory devices projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the therapeutic respiratory devices market?
- Where is the therapeutic respiratory devices market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the therapeutic respiratory devices market today, and over the next 10 years:
- Our 450-page report provides 183 tables and 300 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising therapeutic respiratory devices prices and recent developments.
Segments Covered in the Report
Product
- Inhalers
- Metered Dose Inhalers
- Dry Powder Inhalers
- Soft Mist Inhalers
- Ventilators
- Adult Ventilators
- Neonatal Ventilators
- Humidifiers
- Heated Humidifiers
- Passover Humidifiers
- Integrated Humidifiers
- Built-in Humidifiers
- Stand-alone Humidifiers
- Positive Airway Pressure Devices
- Continuous Positive Airway Pressure Devices
- Auto-titrating Positive Airway Pressure Devices
- Bi-level Positive Airway Pressure Devices
- Oxygen concentrators
- Fixed Oxygen Concentrators
- Portable Oxygen Concentrators
- Nebulizers
- Compressor-based Nebulizers
- Piston-based Hand-held Nebulizers
- Ultrasonic Nebulizers
Application
- Asthma
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Acute Respiratory Failure
- Obstructive Sleep Apnea
- Respiratory Distress Syndrome
- Others
End-users
- Homecare Settings
- Hospitals
- Others
Distribution Channel
- Retail Pharmacies
- Hospitals Pharmacies
- Online Pharmacies
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies and the potential for market growth
3M Health CareAirsep Corporation (Chart Industries)
AptarGroup, Inc.
AstraZeneca
Becton, Dickinson and Company (BD)
Boehringer Ingelheim International GmbH
Cipla Inc.
Fisher & Paykel Healthcare Limited
GE Healthcare
GF Health Products, Inc.
GSK plc
Hamilton Medical
Invacare
Koninklijke Philips N.V.
Medisana GmbH
Medtronic
Merck & Co., Inc.
Novartis AG
OMRON Corporation
Recipharm AB
ResMed
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Smiths Medical, Inc.
Sunovion Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Overall world revenue for Therapeutic Respiratory Devices Market, 2023 to 2033 in terms of value the market will surpass US$63 billion in 2023, this work calculates. We predict strong revenue growth through to 2033. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Therapeutic Respiratory Devices Market, 2023 to 2033 report help you?
In summary, this 450+ page report provides you with the following knowledge:- Revenue forecasts to 2033 for Therapeutic Respiratory Devices Market, 2023 to 2033 Market, with forecasts for product, application, end-users, and distribution channel, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 18 key national markets - See forecasts for the Therapeutic Respiratory Devices Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 25 of the major companies involved in the Therapeutic Respiratory Devices Market, 2023 to 2033.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Therapeutic Respiratory Devices Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Therapeutic Respiratory Devices Market Analysis by Product
5 Therapeutic Respiratory Devices Market Analysis by Application
6 Therapeutic Respiratory Devices Market Analysis by End-user
7 Therapeutic Respiratory Devices Market Analysis by Distribution Channel
8 Therapeutic Respiratory Devices Market Analysis by Region
9 North America Therapeutic Respiratory Devices Market Analysis
10 Europe Therapeutic Respiratory Devices Market Analysis
11 Asia Pacific Therapeutic Respiratory Devices Market Analysis
13 MEA Therapeutic Respiratory Devices Market Analysis
14 Company Profiles
15 Conclusion and Recommendations
Companies Mentioned
- 3M Health Care
- Airsep Corporation (Chart Industries)
- AptarGroup, Inc.
- AstraZeneca
- Becton, Dickinson and Company (BD)
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- Fisher & Paykel Healthcare Limited
- GE Healthcare
- GF Health Products, Inc.
- GSK plc
- Hamilton Medical
- Invacare
- Koninklijke Philips N.V.
- Medisana GmbH
- Medtronic
- Merck & Co., Inc.
- Novartis AG
- OMRON Corporation
- Recipharm AB
- ResMed
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Smiths Medical, Inc.
- Sunovion Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Actavis Generics
- Adherium Limited
- Ai Biomed
- AirPhysio
- Alnylam
- Alveofit
- Apollo Group
- ArtiQ
- BIAL
- BIOCORP
- BreatheSuite
- Carepod
- Chiesi Group
- Cohero Health
- Consort Medical
- Covis Pharma Group
- CUBEX LLC
- Evelo Biosciences, Inc.
- Fluidda
- Glenmark Pharmaceuticals
- H&T Presspart
- HeartWare International, Inc.
- Honeywell
- Iconovo AB
- Ikaria Australia Pty Ltd.
- Inspira Pharmaceuticals
- iPharma Laboratories
- Ivera Medical Corp.
- Leyden Labs
- Lifebit Biotech, Ltd.
- Lupin
- Mallinckrodt International Holdings S.a.r.l.
- Masimo
- Meditab Specialities Ltd.
- Medsmart
- Medspray BV
- Monaghan Medical
- Nanopharm
- NEOGEN
- Neurimmune
- NeuroRx
- Nihon Kohden OrangeMed, Inc.
- NuvoAir
- Nyxoah SA
- Otsuka
- Pharmaxis
- Propeller Health
- Relief Therapeutics
- Rubicon Research Private Limited
- Sandoz
- Scanwell Health
- Senzer Pharmaceuticals
- Sonmol
- Sumitomo Dainippon Pharma America, Inc.
- SunMed
- Tencent AI Lab
- TOA Pharmaceutical Co., Ltd.
- Transpire Bio
- Treo Solutions LLC
- Trudell Medical Limited
- Urovant Sciences
- Valeo Pharma Inc.
- Vectura
- American Lung Association
- Arab Health of Allergy, Asthma & Immunology (AAAAI)
- Asthma and Allergy Foundation of America
- Australian Bureau of Statistics
- Barcelona Institute of Global Health
- Biomedical Advanced Research and Development Authority (BARDA)
- British Lung Foundation (BLF)
- British Thoracic Society
- Centers for Disease Control and Prevention (CDC)
- Cystic Fibrosis Patient Registry
- Drugs Controller General of India (DCGI)
- Eurohealth
- European Commission
- GAVI Alliance
- German Health Insurance Agency
- Getting It Right First Time (GIRFT)
- Institute for Health Metrics and Evaluation (IHME)
- International Study of Asthma and Allergies in Childhood (ISAAC)
- Japanese Respiratory Society
- Korea Disease Control and Prevention Agency (KDCA)
- Ministry of Health of Seguro Popular
- National Asthma Council Australia
- National Center for Biotechnology Information (NCBI)
- National Health Service
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Health (NIH)
- Occupational Lung Disease Statistics
- Primary Care Respiratory Society (PCRS)
- U.S. Census Bureau
- U.S. Food and Drug Administration
- U.S. Health and Human Services
- World Health Organization (WHO)
